Break Up Big Medicine: An Agenda to Restore Power Over the U.S. Health Care System to Patients and Practitioners While Saving Families More Than $6,000 a Year
August 27, 2026 — The Break Up Big Medicine agenda offers reforms that would wrest control over our health care system from Big Medicine, whose fiduciary duty is to investors, and restore it to patients and the practitioners who have sworn an oath to care for them.
Emma Freer’s Testimony at Public Hearing on Atrium Health and WakeMed
August 17, 2026 — Emma Freer testifies in Wake County, North Carolina on Atrium's proposed takeover of WakeMed
Ban Prior Authorization: Ending Big Medicine’s Strategy to Boost Profits by Denying Medically Necessary Care
August 6, 2026 — This policy brief first traces how prior authorization evolved into today’s pervasive corporate care veto, explains the attendant harms, and describes the shortcomings of recent reform efforts. It then proposes a federal ban on prior authorization, prohibiting Big Medicine conglomerates with a financial conflict of interest from both imposing prior authorization requirements and adjudicating requests for coverage.
Out of Practice: How Capital Costs and Corporate Power Are Destroying Independent Medicine
May 7, 2026 — This paper will explore the policy drivers of physician consolidation, the cost of capital for independent practices, and policy solutions to level the playing field. We propose a six-pronged approach to address the unequal burden that independent primary care practices face:
Making Medicine in America Again: Why Breaking Monopolies Is Key to Building a Resilient U.S. Pharmaceutical Manufacturing Base
March 4, 2026 — This paper explains the risks of U.S. dependence on foreign countries for essential medicines and tells the history of how we got here, discusses how successful onshoring of pharmaceutical manufacturing requires restructuring markets by reining in the market power and anti-competitive practices of pharmaceutical middlemen, sets forth a vision and plan for incorporating antimonopoly by design to build deconcentrated pharmaceutical manufacturing market structures, and discusses trade policies to be implemented as competition policies restructure markets and as industrial policies invest in, and create reliable demand for, domestic manufacturing.